Yoshida Yoichiro, Hoshino Seiichiro, Aisu Naoya, Naito Masayasu, Tanimura Syu, Sasaki Takamitsu, Takeno Shinsuke, Yamashita Yuichi
Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Case Rep Oncol. 2014 Feb 19;7(1):117-21. doi: 10.1159/000360132. eCollection 2014 Jan.
Brain metastasis (BM) is rare in colorectal cancer (CRC) patients. Although BM from CRC is a late-stage phenomenon with an extremely poor prognosis, some subsets of patients would benefit from a multidisciplinary management strategy. The prognosis of patients with BM from CRC was associated with the curability of the therapy for BM and the number of metastatic organs. Metastatic brain tumors are generally treated with radiotherapy because many anticancer drugs cannot cross the blood-brain barrier. Here, we present a case treated with XELOX (capecitabine and oxaliplatin) plus bevacizumab for BM from rectal cancer. To our knowledge, this is the first report of a patient who was successfully treated for BM from CRC without radiotherapy. The findings could lead to a paradigm shift in the use of chemotherapy for BM from CRC.
脑转移（BM）在结直肠癌（CRC）患者中较为罕见。尽管CRC发生的BM是一种预后极差的晚期现象，但部分患者亚群可从多学科管理策略中获益。CRC发生BM的患者预后与BM治疗的可治愈性及转移器官数量相关。转移性脑肿瘤通常采用放疗进行治疗，因为许多抗癌药物无法穿过血脑屏障。在此，我们报告一例采用XELOX（卡培他滨和奥沙利铂）联合贝伐单抗治疗直肠癌脑转移的病例。据我们所知，这是首例未进行放疗而成功治疗CRC脑转移患者的报告。这些发现可能会导致CRC脑转移化疗应用模式的转变。
